The University Hospital has for several years of research to determine which patients they are most beneficial to their high cost is bearable for the community.

Kidney cancer is the 10th most common cancer in Belgium. Every year, some 1,600 new patients are confronted with it. If the tumor is detected early and has not generated metastasis, surgical treatment may be sufficient to cure the patient. However, some patients relapse after surgery and still develop metastasis. Furthermore, 30% of kidney cancers are discovered when they are already metastatic. However, existing therapies to halt metastasis have only limited effect in time.

The first product presented in Vienna is a new type of cabozantinib, a tyrosine kinase inhibitor. The second is a new form of immunotherapy nivolumab. Tests on respectively 658 and 821 patients showed that these drugs can reduce about 25% of tumors. They also extend the service life.

Doctors at UZ Leuven participated in both studies. Given the cost of new products, they also conduct research to distinguish patients to whom they would be most beneficial.